PHASQ down 99.0% to $0.000001 on 03 Jan 2026 Market Hours: key concern
PHASQ stock, PhaseBio Pharmaceuticals, Inc., collapsed 99.0% on 03 Jan 2026 during market hours to trade at $0.000001 (PNK, United States, USD). The one-day fall left the stock at a fraction of its 52-week high of $0.0399 and pushed trading volume to 2,500 shares versus a 50-day average of 22,310. This move places PHASQ among today’s top losers, driven by extreme illiquidity and lingering restructuring and clinical risks. We unpack the trade data, key ratios, and what the drop means for holders and speculative traders.
Market move and trading snapshot
PHASQ traded at $0.000001 on 03 Jan 2026 during market hours, down 99.0% from the previous close of $0.000100. Volume registered 2,500 shares versus an average volume of 22,310, highlighting thin liquidity. Day low and day high were both $0.000001, and the stock’s 50-day average price is $0.000236 with a 200-day average of $0.000666 on the PNK exchange in the United States.
Why the stock plunged
The collapse reflects a combination of illiquid trading, a tiny float, and PhaseBio’s history of Chapter 11 reorganization in October 2022, which weighs on market confidence. With market capitalization reported as $0 and shares outstanding not available in public feeds, price moves can be extreme on small orders. MarketBeat coverage flagged the ongoing low-activity trading and corporate uncertainty MarketBeat PHASQ quote and MarketBeat provides regular updates.
Fundamental snapshot
PhaseBio Pharmaceuticals, Inc. remains a clinical-stage biotech focused on cardiovascular assets such as bentracimab (PB2452) and PB1046. Key financials: EPS is -2.14 and reported PE (TTM) is -15.72, cash per share is $1.421879072382421, and book value per share is -3.1646674071776597. The company reports 60 full-time employees and operates in the Biotechnology industry within the Healthcare sector in the United States.
Technical profile and liquidity risks
Technically, PHASQ shows extreme volatility: year high $0.0399 and year low $0.000001, 50-day average price $0.000236, 200-day average $0.000666. Average daily volume of 22,310 contrasts with today’s 2,500 shares, creating large bid-ask gaps and execution risk. These dynamics increase the chance of outsized intraday moves and make standard technical indicators unreliable.
Meyka AI grade and model forecast
Meyka AI rates PHASQ with a score out of 100: Score 63.07 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a base-case 12-month price of $0.00050 versus the current price $0.000001, implying an upside of approximately 49900.00% — forecasts are model-based projections and not guarantees. The model flags high uncertainty driven by clinical-readout risk and severely limited liquidity.
Risks and potential catalysts
Primary risks include further dilution, regulatory or clinical setbacks for PB2452 or PB1046, exchange or OTC listing actions, and the company’s past bankruptcy history. Potential catalysts are successful Phase III data for bentracimab, partnership announcements, or restructuring outcomes; none are guaranteed and each carries high binary risk.
Final Thoughts
PHASQ stock’s 99.0% drop to $0.000001 on 03 Jan 2026 during market hours is an extreme market event driven by acute illiquidity and legacy corporate restructuring. The trade data — 2,500 shares of volume versus a 50-day average of 22,310 — shows a market that can move on very small orders. Fundamental metrics underline the speculative profile: EPS -2.14, PE (TTM) -15.72, cash per share $1.421879072382421 and a negative book value per share of -3.1646674071776597. Meyka AI assigns PHASQ a score of 63.07 (Grade B, HOLD), reflecting mixed signals from sector peers, weak liquidity and uncertain clinical prospects. Meyka AI’s forecast model projects a base-case of $0.00050 in 12 months against the current $0.000001 price, an implied upside of roughly 49900.00% — a model projection, not a promise. For investors, PHASQ remains a high-risk speculative holding suited only to those who accept the possibility of total loss, trading on discrete clinical or restructuring outcomes rather than steady fundamentals. Use limit orders, expect large spreads, and consider portfolio sizing that reflects the elevated tail risk identified in our analysis and grade. Meyka AI provides this as AI-powered market analysis platform insight and not financial advice.
FAQs
PHASQ’s collapse reflects extreme illiquidity, very low trading volume, residual effects from its Chapter 11 history and investor concern about clinical and restructuring outcomes; small orders can move the price dramatically.
Meyka AI rates PHASQ 63.07 out of 100 (Grade B, HOLD). The grade factors in sector comparison, financial metrics, forecasts and analyst signals; it signals mixed fundamentals and elevated risk.
Model projections show possible recovery scenarios — Meyka AI’s forecast base-case is $0.00050, implying large percentage upside versus $0.000001, but forecasts are model-based and not guarantees; outcomes depend on clinical and corporate events.
Key risks are further dilution, clinical trial failure for lead candidates, regulatory setbacks, possible listing actions due to price and liquidity, and limited market depth causing volatile price swings.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
